Cross-sectional and Test-Retest Characterization of PET with [18F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes
| Autor: | Rudolph L. Leibel, Paul L. Harris, Robin Goland, Matthew J. Freeby, Antonella Maffei, Masanori Ichise, Patricia Kringas, Chaitan Divgi |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
0301 basic medicine
Male Cancer Research Fluorine Radioisotopes Test-Retest PET medicine.medical_treatment Tetrabenazine Bioinformatics Insulin-Secreting Cells Insulin Medicine(all) medicine.diagnostic_test Diabetes Middle Aged 3. Good health medicine.anatomical_structure Oncology Positron emission tomography Biomarker (medicine) Female Pancreas Protein Binding Research Article Adult medicine.medical_specialty [18F]FP-(+)-DTBZ Urology Test-retest 03 medical and health sciences VMAT2 Diabetes mellitus medicine Humans Radiology Nuclear Medicine and imaging Beta cell mass Cell Size Demography Type 1 diabetes business.industry Case-control study Binding potential medicine.disease 030104 developmental biology Diabetes Mellitus Type 1 Glucose Diabetes Mellitus Type 2 Case-Control Studies Positron-Emission Tomography Vesicular Monoamine Transport Proteins business |
| Zdroj: | Molecular imaging and biology (2015). doi:10.1007/s11307-015-0888-7 info:cnr-pdr/source/autori:Freeby MJ, Kringas P, Goland RS, Leibel RL, Maffei A, Divgi C, Ichise M, Harris PE./titolo:Cross-sectional and Test-Retest Characterization of PET with [18F]FP-(+)-DTBZ for ? Cell Mass Estimates in Diabetes./doi:10.1007%2Fs11307-015-0888-7/rivista:Molecular imaging and biology/anno:2015/pagina_da:/pagina_a:/intervallo_pagine:/volume Molecular Imaging and Biology |
| ISSN: | 1536-1632 |
| DOI: | 10.1007/s11307-015-0888-7 |
| Popis: | Purpose The vesicular monoamine transporter, type 2 (VMAT2) is expressed by insulin producing β cells and was evaluated as a biomarker of β cell mass (BCM) by positron emission tomography (PET) with [18F]fluoropropyl-dihydrotetrabenazine ([18F]FP-(+)-DTBZ). Procedures We evaluated the feasibility of longitudinal pancreatic PET VMAT2 quantification in the pancreas in two studies of healthy controls and patients with type 1 or 2 diabetes. VMAT2 binding potential (BPND) was estimated voxelwise using a reference tissue method in a cross-sectional study, followed by assessment of reproducibility using a test-retest paradigm. Metabolic function was evaluated by stimulated c-peptide measurements. Results Pancreatic BPND was significantly decreased in patients with type 1 diabetes relative to controls and the test-retest variability was 9.4 %. Conclusions Pancreatic VMAT2 content is significantly reduced in long-term diabetes patients relative to controls and repeat scans are sufficiently reproducible to suggest the feasibility clinically VMAT2 measurements in longitudinal studies of new onset diabetes. Electronic supplementary material The online version of this article (doi:10.1007/s11307-015-0888-7) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|